NCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02239679 2018-08-24
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02632110 2018-01-18
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02628236 2017-09-18
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02281136 2017-01-13
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT01475955 2016-10-28
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02799030 2016-07-19
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
Biofrontera Bioscience GmbH
Phase 2 Completed
NCT00002975 2013-10-10
Photodynamic Therapy in Treating Patients With Skin Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01458587 2013-03-14
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT00865878 2011-10-21
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
DUSA Pharmaceuticals, Inc.
Phase 2 Terminated